Clinical Trial Update: Omalizumab to Treat Hyper-IgE (Job's) Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial of omalizumab for Hyper-IgE Syndrome (Job's Syndrome) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyper-ige Syndrome
• Job Syndrome

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hyper-IgE Syndrome, Job's Syndrome | Phase 1 | Status: COMPLETED